(IN BRIEF) Scientists at the University of Southampton have engineered a new type of super-strong antibody, which could significantly enhance immune system responses in cancer patients. By altering the shape and rigidity of antibodies, the team discovered that these modified … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged antibodies, antibody engineering, Cancer Immunotherapy, Cancer Research UK, cancer treatment, disulfide bonds, immune response, immune system, immunotherapy, Isabel Elliott, Ivo Tews, Mark Cragg, Nature Communications, rigid antibodies, structural biology, super-strong antibody, University of Southampton
(IN BRIEF) Empa researchers have developed a printable, non-swelling hydrogel made from cold-water fish gelatin, enabling the creation of 3D living skin models. Designed to replicate the full complexity of human skin, including its layered architecture and cellular composition, the … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Switzerland, Technology
Tagged 3D bioprinting, artificial skin, biointerfaces, biologically compatible materials, biomimetic membranes, biotechnology, cod gelatin, cold-water fish gelatin, customized wound dressing, electrospinning, Empa, Empa Biomimetic Membranes and Textiles, Empa Laboratory for Biointerfaces, extracellular matrix, gelatin-based material, hydrogel, immune response, Kongchang Wei, Medical Innovation, non-swelling hydrogel, personalized medicine, printable hydrogel, Regenerative medicine, skin disease research, SKINTEGRITY.CH, Swiss research, synthetic skin models, Tissue Engineering, University Medicine Zurich, wound healing
(IN BRIEF) GSK has announced that the FDA has accepted its application to review a prefilled syringe version of Shingrix, its shingles vaccine. This new version, expected to be available from January 2025, eliminates the need for reconstitution, offering a … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged administration, adults 50 and over, antigen, AS01B adjuvant system, chickenpox, FDA, glycoprotein E, GSK, healthcare community, healthcare professionals, immune response, immunodeficiency, immunosuppression, liquid adjuvant, lyophilised, non-live vaccine, Prefilled Syringe, recombinant subunit vaccine, Recombinant Zoster Vaccine, reconstitution, RZV, safety, Shingles, shingles prevention, shingles vaccine, Shingrix, Shingrix approval, vaccine composition, Vaccine Innovation, vaccine presentation, vaccine safety, varicella, varicella-zoster virus
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?